STOCK TITAN
  1. Home
  2. News
  3. SNGX

Soligenix Inc - SNGX STOCK NEWS

Welcome to our dedicated news page for Soligenix (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Soligenix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Soligenix's position in the market.

News
Soligenix Announces Pricing of $4.75 Million Public Offering
Rhea-AI Summary
Soligenix, Inc. (Nasdaq: SNGX) has announced the pricing of a $4.75 million public offering, consisting of 11,875,000 shares of common stock and warrants. The offering includes common stock equivalents and warrants to purchase additional shares at $0.40 per share. The gross proceeds are estimated at $4.75 million before expenses. The warrants have an exercise price of $0.40 per share and a five-year expiration period. The offering is set to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Rhea-AI Summary
Soligenix, Inc. receives FDA orphan drug designation for MarVax™ heat stable vaccine against Marburg marburgvirus infection, providing market exclusivity and financial benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.51%
Tags
clinical trial
-
News
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Rhea-AI Summary
Soligenix, Inc. receives orphan drug designation from the FDA for SuVax™ Heat Stable Vaccine, providing seven years of market exclusivity upon approval. The vaccine targets Sudan ebolavirus, offering potential prevention and post-exposure prophylaxis. Soligenix's novel vaccine platform shows promise in addressing rare diseases with unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.05%
Tags
clinical trial
News
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Rhea-AI Summary
Soligenix, Inc. announces agreement from the European Medicines Agency for a Phase 3 study on HyBryte™ in treating cutaneous T-cell lymphoma. The 18-week study aims to replicate and extend results from a previous successful study, with top-line results expected in the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.15%
Tags
none
-
News
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
Rhea-AI Summary
Soligenix, Inc. (SNGX) reports its financial results for the year ended December 31, 2023, highlighting advancements in clinical programs, FDA discussions, and successful trial results. The company's revenue was $0.8 million, with a net loss of $6.1 million. Soligenix maintains a cash position of $8.4 million, focusing on managing cash burn and exploring strategic options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
earnings
-
News
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Rhea-AI Summary
Soligenix, Inc. announces the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to aid in the clinical development of SGX945 (dusquetide) for the treatment of Behçet's Disease. The MAB will be comprised of internationally renowned rheumatologists with extensive experience in Behçet's Disease. The Phase 2a clinical study of SGX945 in Behçet's Disease is set to initiate in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
management
News
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Rhea-AI Summary
Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Soligenix, a late-stage biopharmaceutical company, has made significant advancements in its product pipeline, with its lead clinical asset, HyBryte™ or SGX301, showing positive results in a Phase 3 study. The company is also progressing with SGX302 for psoriasis and SGX203 for pediatric Crohn's disease. Additionally, Soligenix has achieved milestones in public health solutions, including promising data from its filovirus vaccine program. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite, global footprint, and recent milestones in defense deals. The company is financially robust and poised to shift its revenue focus from hardware to Software-as-a-Service (SaaS) and recurring cybersecurity revenues from 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.04%
Tags
none
-
News
Soligenix to Present at The Microcap Conference
Rhea-AI Summary
Soligenix, Inc. (Nasdaq: SNGX) will present at The Microcap Conference in Atlantic City, N.J., focusing on developing and commercializing products to treat rare diseases with unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences
-
News
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
Rhea-AI Summary
Soligenix, Inc. (Nasdaq: SNGX) has received 'Fast Track' designation from the FDA for its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet's Disease. This designation allows for an expedited review process and potential NDA submission on a rolling basis, with priority review eligibility, indicating a significant milestone for the company's biopharmaceutical development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.05%
Tags
clinical trial
News
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Rhea-AI Summary
Soligenix, Inc. (Nasdaq: SNGX) announced preliminary top-line results of its ongoing Phase 2a trial of SGX302 for the treatment of mild-to-moderate psoriasis. The expanded portion of the trial (Cohort 2) showed clinical success in patients, with two reaching an 'Almost Clear' disease status, and a mean drop of approximately 50% in the Psoriasis Activity and Severity Index (PASI) score. The company plans to pursue SGX302 in psoriasis treatment and explore other disease indications, including non-orphan indications, where there remains an unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
clinical trial
Stock SNGX logo
Soligenix Inc

Nasdaq:SNGX

SNGX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SNGX Stock Data

4.06M
10.48M
0.1%
3.66%
1.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Princeton

About SNGX

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.